Based on its role in tumour formation and progression, targeted therapy against mTOR has been shown to decrease tumour growth in model systems[10,11] and several mTOR inhibitors, such as everolimus, deforolimus and temsirolimus, have been used in clinical trials for the treatment of multiple cancer types including breast cancer[12]. The gene discussed is MTOR; the disease is breast carcinoma.